- Medicare is implementing a ‘most favored nation’ pricing model for GLP-1RAs like Ozempic and Wegovy to lower drug costs.
- This policy aims to align U.S. drug prices with those paid by comparable high-income countries within the OECD.
- The administration estimates potential savings of up to $15 billion for Medicare and beneficiaries by 2027.
- The pricing model bases reimbursement rates on the median prices paid by Canada, UK, Germany, France, and Japan.
- Success depends on manufacturer cooperation, patient utilization, and ensuring sufficient drug supply to meet demand.
Medicare’s adoption of a most favored nation (MFN) pricing model for glucagon-like peptide-1 receptor agonists (GLP-1RAs) marks a pivotal shift in U.S. pharmaceutical policy, aiming to align domestic drug costs with those in comparable high-income nations. Announced in November 2025, the policy targets blockbuster medications like Ozempic, Wegovy, Mounjaro, and Zepbound, which have seen explosive demand for both type 2 diabetes and obesity treatment. By legally binding U.S. prices to the median rates paid by countries in the OECD, the administration projects savings of up to $15 billion for Medicare and beneficiaries over the next five years—though long-term fiscal balance hinges on manufacturer cooperation, utilization trends, and potential supply constraints.
International Price Comparisons Drive U.S. Policy
Under the MFN framework, the U.S. Department of Health and Human Services (HHS) is required to set Medicare reimbursement rates for GLP-1RAs at or below the median price paid by five peer nations: Canada, the United Kingdom, Germany, France, and Japan. Data from the Organisation for Economic Co-operation and Development (OECD) show that, as of late 2024, the average cost per dose of semaglutide (the active ingredient in Ozempic and Wegovy) was 58% lower in these countries than in the U.S. For instance, a month’s supply of Wegovy cost $1,349 in the U.S. versus $567 in Germany and $320 in Canada. The new pricing mechanism leverages this disparity, mandating that U.S. prices not exceed 100% of the median international benchmark. Early estimates from the Congressional Budget Office suggest this could reduce Medicare Part D spending on GLP-1s by $3.2 billion annually by 2027, assuming full compliance and stable prescribing patterns.
Key Players: Pharma Giants and Federal Regulators
The policy directly involves pharmaceutical manufacturers Novo Nordisk, Eli Lilly, and, to a lesser extent, Pfizer and AstraZeneca, whose GLP-1 or dual agonist drugs fall under the new pricing umbrella. Novo Nordisk, which produces Ozempic and Wegovy, initially resisted the rule, filing a pre-enforcement challenge citing concerns over intellectual property and pricing sovereignty. Eli Lilly, manufacturer of Mounjaro and Zepbound, adopted a more strategic posture, negotiating volume guarantees in exchange for phased price reductions. Meanwhile, the Centers for Medicare & Medicaid Services (CMS) and HHS have positioned the MFN rule as a cornerstone of President Biden’s broader drug affordability agenda. The Federal Trade Commission is monitoring for anti-competitive behavior, particularly regarding allocation strategies that could limit access to lower-priced doses for Medicare patients.
Trade-Offs: Savings vs. Innovation and Access
The MFN policy presents a complex trade-off between immediate fiscal relief and long-term market dynamics. On one hand, reduced prices could expand access for Medicare beneficiaries, particularly older adults with diabetes who have faced high out-of-pocket costs. However, stakeholders warn that compressed margins may disincentivize R&D investment in next-generation metabolic therapies. A 2025 analysis by the Tufts Center for the Study of Drug Development estimated that a 40% price cut across GLP-1 portfolios could reduce projected industry returns by 12–15 percentage points, potentially delaying new indications for cardiovascular and neurodegenerative diseases. Additionally, manufacturers might respond by limiting supply to the U.S. market or prioritizing higher-margin private insurers, risking shortages for public program enrollees. The policy also raises equity concerns, as lower prices could be offset by stricter prior authorization requirements or formulary restrictions.
Timing: Why the Window Closed in 2025
The policy emerged amid converging pressures: record Medicare drug expenditures, public outrage over drug pricing, and expiring patent protections for certain biologics. In 2024, Medicare spent over $8.7 billion on GLP-1RAs, a 200% increase from 2022, driven by rising obesity rates and expanded clinical guidelines. Simultaneously, international pressure mounted as U.S. prices drew criticism from G7 health ministers, and domestic legal pathways matured following the Inflation Reduction Act’s drug negotiation provisions. The November 2025 announcement capitalized on a narrow regulatory window—before major patent cliffs for semaglutide in 2027—allowing HHS to assert pricing authority while brand-name manufacturers still dominate the market. Delaying action risked losing leverage to generic entrants and fragmented pricing contracts.
Where We Go From Here
Over the next 12 months, three scenarios could unfold. First, full compliance and price alignment could yield projected savings, with manufacturers accepting lower margins in exchange for volume and regulatory stability. Second, protracted litigation or supply rationing could delay implementation, forcing CMS to invoke emergency pricing powers or expand 340B pharmacy access. Third, manufacturers might shift focus to combination therapies or non-Medicare markets, reducing innovation in standalone GLP-1 drugs. Each path will test the resilience of Medicare’s pricing authority and the balance between affordability and sustainable innovation.
Bottom line — while the most favored nation policy offers a bold mechanism to control drug costs, its success depends on navigating manufacturer resistance, maintaining patient access, and preserving incentives for future medical breakthroughs.
Source: MedicalXpress